Notwithstanding numerous setbacks, several MDM2 inhibitors have now progressed into late-phase clinical enhancement. New approaches have also been created to enhance the efficacy of MDM2 inhibitors and also to mitigate their on-target toxicity. During this overview, we summarize the progress and troubles in the development of the MDM2 focused therapy. https://barbarav000rkb0.jasperwiki.com/user